Xultophy 100/3.6 Market Report 2026

Xultophy 100/3.6 Market Overview

• The Xultophy 100/3.6 market growth in the historic period has been driven by rising prevalence of type 2 diabetes, expansion of insulin therapy usage • Market expansion is supported by expansion of combination therapy adoption, increasing demand for simplified diabetes treatment regimens • Growth Driver: Rising Type 2 Diabetes Prevalence Driving Growth In The Market • North America was the largest region in 2025.

What Is Covered Under Xultophy 100/3.6 Market?

Xultophy 100/3.6 is a combination injectable medication containing 100 units/mL of insulin degludec and 3.6 mg/mL of liraglutide, used to manage type 2 diabetes. It helps improve glycemic control alongside diet and exercise, offering a once-daily option that addresses both insulin deficiency and glucagon-like peptide-1 (GLP-1) receptor activity. The main indication types of xultophy 100/3.6 is type 2 diabetes mellitus. Type 2 diabetes mellitus (T2DM) is a chronic medical condition in which the body becomes resistant to the effects of insulin, or when the pancreas does not produce enough insulin to maintain normal blood glucose levels. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies and are also used by various end users such as adults, and geriatric.

What Is The Xultophy 100/3.6 Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of combination therapy adoption, increasing demand for simplified diabetes treatment regimens, growing focus on weight-neutral glycemic control, rising investments in metabolic disorder treatments, development of next-generation injectable combinations. Major trends in the forecast period include increasing adoption of fixed-ratio combination diabetes therapies, rising preference for once-daily injectable treatments, increasing focus on glycemic control optimization, expansion of glp-1 based combination products, enhanced emphasis on patient adherence.

Global Xultophy 100/3.6 Market Segmentation

1) By Indication: Type 2 Diabetes Mellitus, Others 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Xultophy 100/3.6 Market?

The increasing prevalence of type 2 diabetes is expected to propel the growth of the xultophy 100/3.6 market going forward. Type 2 diabetes is a chronic condition characterized by insulin resistance and insufficient insulin production, leading to high blood sugar levels. The increasing prevalence of type 2 diabetes is due to rising obesity rates, sedentary lifestyles, poor dietary habits, and genetic predisposition. Xultophy 100/3.6 helps type 2 diabetes patients by combining insulin degludec and liraglutide in a single formulation, offering improved blood sugar control, reducing the number of injections required, and supporting better adherence to treatment regimens while minimizing the risk of hypoglycemia and weight gain. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, more than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes. Therefore, the increasing prevalence of type 2 diabetes drives the xultophy 100/3.6 industry. The growing geriatric population is expected to boost the growth of the xultophy 100/3.6 market going forward. The geriatric population refers to individuals who are generally 65 years of age or older, and it encompasses the elderly who may experience various health, social, and functional changes due to aging. The growing geriatric population is attributed to factors such as advancements in healthcare, improved living conditions, better nutrition, and increased life expectancy. Xultophy 100/3.6 helps geriatric population patients by providing a convenient and effective treatment option that reduces the frequency of daily interventions, supports better adherence to prescribed regimens, minimizes common side effects such as low blood sugar episodes, and promotes overall health management tailored to the needs of older adults. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is driving growth in the xultophy 100/3.6 industry. Rising healthcare expenditure is expected to drive the xultophy 100/3.6 market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure supports xultophy 100/3.6 by enabling increased investment in innovative combination therapies, improving patient access through subsidized programs and insurance coverage, funding awareness campaigns for advanced treatment options, and facilitating research and development initiatives to optimize treatment outcomes and address growing healthcare needs. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, rising healthcare expenditure drives the xultophy 100/3.6 industry.

Key Players In The Global Xultophy 100/3.6 Market

Major companies operating in the xultophy 100/3.6 market are Novo Nordisk A/S

Regional Insights

North America was the largest region in the xultophy 100/3.6 market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Xultophy 100/3.6 Market?

The xultophy 100/3.6 market consists of sales of the prefilled pen for subcutaneous injection and needles. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xultophy 100/3.6 Market Report 2026?

The xultophy 100/3.6 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xultophy 100/3.6 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.